Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma

Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small ...
CityNews Montreal

REM introduces two train directions during testing phase

REM users will need to pay closer attention before boarding their train starting Friday, as a new phase of testing begins ahead of the planned opening of the Anse-à-l’Orme branch this spring. Transit ...